Arbutus Presents New Data on AB-729, AB-836 and AB-101 at

AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients...

Related Keywords

William Collier ,Fung Yuen ,Arbutus Biopharma Corporation Nasdaq ,Division Of Gastroenterology ,Deputy Head Of Department ,University Of Hong Kong ,International Liver Congress ,Webcast Scheduled ,Biopharma Corporation ,European Association ,Chief Executive Officer ,Data Poster ,Man Fung Yuen ,Deputy Head ,Lap Chee ,Hong Kong ,Nasdaq Abus ,Arbutus Biopharma Corporation ,Arbutus ,Arbutus Biopharma ,Asl 2022 ,Hronic Hbv ,Gbv ,Asl Poster Presentations ,Asl Ilc 2022 ,